Massive study of 2 million AF patients reveals Real-World impact of blood thinners
NCT ID NCT05838664
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study analyzed data from over 2 million people in France with atrial fibrillation (an irregular heart rhythm) to compare outcomes between those who took blood thinners and those who did not. Researchers looked at rates of stroke, major bleeding, and death between 2016 and 2020 using a national health database. The goal was to understand how well these medications work in everyday practice, outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oral anticoagulants (blood thinners: apixaban, rivaroxaban, dabigatran, warfarin)
What this could lead to
If successful, this study could help doctors better understand the real-world benefits and risks of blood thinners for atrial fibrillation patients, potentially improving treatment guidelines.
What could go wrong
This is a retrospective study using existing data, not a controlled experiment. It can show patterns but cannot prove cause and effect. Results may not apply to all patient groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Investigational Site
Paris, France